Glaukos
Glaukos commences trials for its third-generation keratoconus therapy
Glaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. The ophthalmic medical ...
Aussie study offers new MIGS head-to-head comparison
Australian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no ...
Dr Nathan Kerr performs Victorian-first PRESERFLO MicroShunt procedure
Glaucoma surgeon Dr Nathan Kerr has performed Victoria’s first procedure with the PRESERFLO MicroShunt, first approved by the Therapeutic Goods ...
Glaukos trials eyelid cream to treat presbyopia and dry eye
Glaukos has commenced Phase 2 trials of two investigational cream-based drug candidates that are applied to the eyelids to treat ...
Ivantis to pay Glaukos US$60 million in MIGS patent settlement
MIGS device manufacturer Glaukos has reached an agreement with Ivantis over a patent infringement lawsuit regarding the latter’s Hydrus Microstent ...
Glaukos pens new deal for Preserflo MicroShunt
Glaukos has signed a new license agreement with Santen Pharmaceutical for the Preserflo MicroShunt, obtaining exclusive rights for the therapy ...
Glaukos introduces the iprism SX
Glaukos has unveiled a new single-use surgical gonioscopy lens that is said to provide exceptional clarity with expanded views of ...
Sector embraces government approval of standalone MIGS
From this month, surgeons can perform standalone minimally invasive glaucoma surgery (MIGS) under Medicare, seeing Australia become the first major ...